{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:40Z","timestamp":1790352580939,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40262-025-01552-x","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T16:01:18Z","timestamp":1755100878000},"page":"1465-1476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab"],"prefix":"10.1007","volume":"64","author":[{"given":"Jianning","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7527-1897","authenticated-orcid":false,"given":"Akihiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pavese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wojtkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Matsangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasu","family":"Poondru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"3","key":"1552_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1552_CR2","first-page":"CD004064","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NLX, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 24","key":"1552_CR3","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1002\/cncr.30881","volume":"123","author":"MA Jim","year":"2017","unstructured":"Jim MA, Pinheiro PS, Carreira H, Espey DK, Wiggins CL, Weir HK. Stomach cancer survival in the United States by race and stage (2001\u20132009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):4994\u20135013.","journal-title":"Cancer"},{"issue":"10060","key":"1552_CR4","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","volume":"388","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654\u201364.","journal-title":"Lancet"},{"issue":"1","key":"1552_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","journal-title":"Gastric Cancer"},{"issue":"10","key":"1552_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"key":"1552_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155145","volume":"254","author":"V Angerilli","year":"2024","unstructured":"Angerilli V, Ghelardi F, Nappo F, Grillo F, Parente P, Lonardi S, et al. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: a literature review with expert opinion. Pathol Res Pract. 2024;254:155145.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"1552_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1552_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00385-1","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10(1):38.","journal-title":"Biomark Res"},{"issue":"12","key":"1552_CR10","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.21873\/anticanres.13919","volume":"39","author":"JH Baek","year":"2019","unstructured":"Baek JH, Park DJ, Kim GY, Cheon J, Kang BW, Cha HJ, et al. Clinical implications of claudin18.2 expression in patients with gastric cancer. Anticancer Res. 2019;39(12):6973\u20139.","journal-title":"Anticancer Res"},{"key":"1552_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00543","volume":"8","author":"R Waters","year":"2024","unstructured":"Waters R, Sewastjanow-Silva M, Yamashita K, Abdelhakeem A, Iwata KK, Moran D, et al. Retrospective study of claudin 18 isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma. JCO Precis Oncol. 2024;8:e2300543.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1552_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47178-6","volume":"13","author":"HD Kim","year":"2023","unstructured":"Kim HD, Choi E, Shin J, Lee IS, Ko CS, Ryu MH, et al. Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. Sci Rep. 2023;13(1):20047.","journal-title":"Sci Rep"},{"issue":"9","key":"1552_CR13","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, T\u00fcreci \u00d6. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49(9):870\u20136.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"1552_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609\u201319.","journal-title":"Ann Oncol"},{"issue":"10389","key":"1552_CR15","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","journal-title":"Lancet"},{"issue":"8","key":"1552_CR16","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","journal-title":"Nat Med"},{"issue":"9","key":"1552_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"\u00d6 T\u00fcreci","year":"2019","unstructured":"T\u00fcreci \u00d6, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019;30(9):1487\u201395.","journal-title":"Ann Oncol"},{"issue":"19","key":"1552_CR18","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, et al. ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2023;29(19):3882\u201391.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1552_CR19","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1111\/cts.70280","volume":"18","author":"A Yamada","year":"2025","unstructured":"Yamada A, Takeuchi M, Komatsu K, Bonate PL, Poondru S, Yang J. Population PK and exposure-response analyses of zolbetuximab in patients with locally advanced unresectable or metastatic G\/GEJ adenocarcinoma. Clin Transl Sci. 2025;18(7):e70280.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"1552_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JCO.2007.11.0304","volume":"26","author":"RK Ramanathan","year":"2008","unstructured":"Ramanathan RK, Egorin MJ, Takimoto CHM, Remick SC, Doroshow JH, LoRusso PA, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008;26(4):563\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1552_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jphs.2024.08.005","volume":"156","author":"F Kinugasa","year":"2024","unstructured":"Kinugasa F, Kajikawa S, Weng J, Ugawa T, Fushiki H, Yamanaka Y, et al. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets. J Pharmacol Sci. 2024;156(3):161\u201370.","journal-title":"J Pharmacol Sci"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01552-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:48:58Z","timestamp":1759146538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01552-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01552-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"14 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kohei Shitara received personal fees for consulting and advisory roles from ALX Oncology, Amgen, Arcus Biosciences, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline K.K., Guardant Health Japan, Healios K.K., Janssen, Merck, Moderna, Novartis, Ono Pharmaceutical, Takeda, and Zymeworks; honoraria from Astellas, AstraZeneca, Bristol Myers Squibb, Janssen, and Ono Pharmaceutical; and research funding (all to institution) from Amgen, Astellas, AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eisai, Merck, Ono Pharmaceutical, PPD-SNBL K.K., PRA Health Sciences, Taiho Pharmaceutical, and Toray, outside the submitted work. Rui-Hua Xu has nothing to report. David Ilson has nothing to report. Sara Lonardi served as consultant\/advisor for Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, GSK, Helion, Incyte, Lilly, Merck Serono, MSD, Nimbus Therapeutics, Rottapharm, Servier, and Takeda; and invited speaker for Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Incyte, Lilly, Merck Serono, MSD, Pierre Fabre, Roche, and Servier. Samuel J. Klempner served as consultant\/advisor for Astellas, AstraZeneca, Bristol Myers Squibb, Coherus BioSciences, Daiichi Sankyo, Merck, Mersana Therapeutics, Natera, Novartis, Roche, Sanofi-Aventis, Scandion Oncology, and Servier; and reports prior stock\/equity in Nuvalent and Turning Point Therapeutics. Jianning Yang, Akihiro Yamada, Yoko Ueno, Masato Takeuchi, Janet Pavese, Maria Matsangou, and Srinivasu Poondru are employees of Astellas. Tomasz Wojtkowski was an employee of Astellas at the time the study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The research reported in this article was sponsored by Astellas Pharma, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Details for how researchers may request access to anonymized participant level data, trial level data and protocols from Astellas sponsored clinical trials can be found at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Conceptualization: Jianning Yang and Srinivasu Poondru; methodology: Jianning Yang, Akihiro Yamada, and Srinivasu Poondru; formal analysis and investigation: Jianning Yang, Akihiro Yamada, Kohei Shitara, David Ilson, Sara Lonardi, Samuel J. Klempner, Yoko Ueno, Masato Takeuchi, Janet Pavese, Tomasz Wojtkowski, and Maria Matsangou; writing\u2014original draft preparation: Jianning Yang and Akihiro Yamada; writing\u2014review and editing: Jianning Yang, Akihiro Yamada, Kohei Shitara, Rui-Hua Xu, David Ilson, Sara Lonardi, Samuel J. Klempner, Yoko Ueno, Masato Takeuchi, Janet Pavese, Tomasz Wojtkowski, Maria Matsangou, and Srinivasu Poondru; and supervision: Srinivasu Poondru. All authors participated in the critical review and revision of this manuscript and provided approval of the manuscript for submission.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}